Analysts Increase Their Projections for Exact Sciences After Strong Q3 Performance

Strong Financial Performance: Exact Sciences Corporation reported third-quarter earnings of 24 cents per share, surpassing analyst expectations of a loss, and quarterly sales of $850.739 million, exceeding estimates of $810.178 million.

Increased Sales Guidance: The company raised its FY2025 sales guidance from $3.130 billion-$3.170 billion to $3.220 billion-$3.235 billion, reflecting confidence in its growth strategy.

Positive Market Reaction: Following the earnings announcement, Exact Sciences shares rose by 3.5%, closing at $66.98.

Analyst Upgrades: Several analysts adjusted their price targets for Exact Sciences, with BTIG raising it from $75 to $85, Stifel from $67 to $80, and Barclays from $65 to $77, all maintaining a positive outlook on the stock.